Progyny, inc. announces unaudited consolidated financial results for the three month and nine months period ended september 30, 2019; provides financial guidance for the three-month period and year ended december 31, 2019
Progyny, inc. announced unaudited consolidated financial results for the three month and nine months period ended september 30, 2019. for the quarter, revenue was $61,196,000 against $27,798,000 a year ago. net loss from continuing operations was $8,210,000 or $1.10 per share against $1,137,000 or $0.20 per share a year ago. income from continuing operations was $3,069,000 against loss of $587,000 a year ago.for the nine months, revenue was $164,561,000 against $76,213,000 a year ago. net loss from continuing operations was $4,169,000 or $0.70 per share against $3,539,000 or $0.70 per share a year ago. income from continuing operations was $8,533,000 against loss of $2,749,000 a year ago.the company is providing the financial guidance for both the three-month period and year ended december 31, 2019. for the fourth quarter, revenue is projected to be $65.0 million to $66.5 million, reflecting growth of 123% to 128%. net loss from continuing operations is projected to be $4.4 million to $4.7 million, reflecting a $5.8 million non-cash charge associated with the final valuation re-measurement of the convertible preferred stock warrants.for the full year, revenue is projected to be $229.6 million to $231.1 million, reflecting growth of 118% to 119%. net loss from continuing operations is projected to be $8.6 million to $8.9 million, reflecting $18.2 million of non-cash charges associated with the valuation re-measurement of the convertible preferred stock warrants.
